EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Radioligand Therapy in Cancer Management: A Global Perspective

Gaia Ninatti iD, Sze Ting Lee iD, Andrew M Scott iD

Cancers · 23.10.2025 · 17 (21) · 3412

DOI: 10.3390/cancers17213412 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 23.10.2025. Verfasst von Gaia Ninatti und 2 weiteren Autor:innen. Beteiligte Einrichtung: Olivia Newton-John Cancer Research Institute, Heidelberg, Melbourne, VIC 3084, Australia. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radioligand therapy (RLT) is a targeted treatment modality that combines a tumour-specific ligand with a therapeutic radionuclide. Once administered, the radiopharmaceutical binds selectively to cancer-associated targets, delivering cytotoxic radiation directly to tumour cells while sparing surrounding tissues. Two RLT agents, [177Lu]Lu-DOTA-TATE (Lutathera®) and [177Lu]Lu-PSMA-617 (Pluvicto®), have received regulatory approval for the treatment of advanced gastroenteropancreatic neuroendocrine tumours and metastatic castration-resistant prostate cancer, respectively. As of July 2025, more than 400 clinical trials are registered, exploring novel molecular targets such as FAP, CAIX, and GRPR, as well as alternative radionuclides and combination regimens in both solid and haematologic malignancies. In this review, we describe the design principles and mechanisms of action of RLT, summarise clinical evidence for approved and emerging radiopharmaceuticals, and discuss current global disparities in access and availability. Finally, we outline the main clinical challenges, including fixed dosing regimens, resistance, toxicity, and variability in patient selection and response assessment. Continued research to optimise radiopharmaceutical design, together with investment in infrastructure, workforce capacity, and international collaboration, will be essential to expand access and realise the full potential of RLT as a leading treatment strategy in modern oncology.

Schlagwörter

Stichwörter der Autor:innen

[177Lu]Lu-DOTA-TATE[177Lu]Lu-PSMA-617neuroendocrine tumoursprostate cancerradioligand therapytheranostics

Autor:innen und Institutionen

  • Olivia Newton-John Cancer Research Institute, Heidelberg, Melbourne, VIC 3084, Australia.
  • Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Melbourne, VIC 3084, Australia.
  • School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.
  • School of Cancer Medicine, La Trobe University, Bundoora, Melbourne, VIC 3086, Australia.
  • School of Health and Biomedicine, RMIT University, Melbourne, VIC 3000, Australia.
  • Faculty of Medicine, University of Melbourne, Parkville, Melbourne, VIC 3052, Australia.

ORCID-Profile: Gaia Ninatti, Sze Ting Lee, Andrew M Scott

Zitieren

APA

Ninatti, G., Lee, S. T., & Scott, A. M. (2025). Radioligand Therapy in Cancer Management: A Global Perspective. Cancers, 17(21), 3412. https://doi.org/10.3390/cancers17213412

Vancouver

Ninatti G, Lee ST, Scott AM. Radioligand Therapy in Cancer Management: A Global Perspective. Cancers. 2025;17(21):3412. doi:10.3390/cancers17213412

BibTeX
@article{Ninatti2025,
  author = {Ninatti, Gaia and Lee, Sze Ting and Scott, Andrew M},
  title = {Radioligand Therapy in Cancer Management: A Global Perspective},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {21},
  pages = {3412},
  doi = {10.3390/cancers17213412}
}
Kostenlos starten →